Interstitial Lung Disease Market is expected to be valued at US$ 2,453.5 Mn with CAGR of 6.5% by 2028 | MSD (Merck), Liminal Biosciences, Glenmark Pharma, J.B. Chemicals & Pharmaceuticals

Symptoms of Interstitial lung disease are usually shortness of breath and a dry cough, the condition can progress to include muscle and joint pain and fatigue. Advanced stages of the disease may also lead to heart and lung complications, including enlargement of the fingers and toes. Cyanosis, a blue coloration of the skin due to reduced oxygen levels, may also occur. Blood tests are often necessary to determine whether another autoimmune disease is the cause. Treatment for ILD is based on severity and type of ILD. Treatment does not cure the disease, although it can slow its progression. Treatments for the condition depend on its severity, the cause of the disease, and the individual’s symptoms. Mild cases may be stable without medical treatment.

Get PDF Sample Copy of Report (Including Full TOC, List of Tables & Figures, Chart) @ https://www.coherentmarketinsights.com/insight/request-sample/4798

For instance, according to a report published 2017, in European Respiratory Journal, 1170 interstitial lung disease cases were reported. The overall prevalence was 97.9 and incidence: 19.4/year in Paris and France. The most prevalent diagnoses were sarcoidosis (42.6%), connective tissue diseases associated ILDs (CTDs-ILDs) (16%), idiopathic pulmonary fibrosis (IPF) (11.6%), and occupational ILDs (5.0%).

Global Interstitial Lung Disease Market – Impact of the Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic and lockdown in various countries across the globe have impacted the financial status of businesses across all sectors. The private healthcare sector is one such sector, which has been majorly impacted by the pandemic. Cancer patients in general and those suffering from lung cancer in particular are a vulnerable group because of their various intrinsic characteristics and care needs. Lung cancer patients require frequent radiologic study follow-ups, which had been affected due to COVID-19 pandemic. COVID-19 related incidental radiologic findings can appear in routinely scheduled radiology tests, which may be difficult to interpret. Moreover, cancer treatment induced pneumonitis may have similar radiologic features similar to those in acute SARS-CoV-2 pneumonia and lead to a wrong diagnosis. The different health care needs, the requirement for continuous health care access and follow-ups, and the clinical trials in which this patient population might be enrolled are all being affected by the current COVID-19 health crisis. Due to COVID-19 pandemic health care providers and institutions faced difficult situations and challenging ethical scenarios.

The global interstitial lung disease market is estimated to be valued at US$ 1,578.9 Mn in 2021 and is expected to exhibit a CAGR of 6.5% over the forecast period (2021-2028).

Growing number of drug approvals from regulatory bodies is driving the market growth

Key players are focusing on gaining drug approvals from regulatory bodies is augmenting the growth of global interstitial lung disease market during the forecast period. For instance, in April 2021, United Therapeutics Corporation, a biotechnology company, announced that the U.S. Food and Drug Administration (FDA) had approved Tyvaso (treprostinil) Inhalation Solution for the treatment of patients with pulmonary hypertension associated with interstitial lung disease to improve exercise ability.

Increasing adoption of inorganic strategies by the market players is projected to foster the market growth during the forecast period.

Increasing number of partnerships by key players are projected to augment the growth of global interstitial lung disease market over the forecast period. For instance, in September 2020, Boehringer Ingelheim (Canada) Ltd., a pharmaceutical company, announced that they had entered into partnership with the University Hospital Foundation (UHF), this partnership will focus on improving patient outcomes in the area of progressive fibrosing interstitial lung disease (PF-ILD).

Global Interstitial Lung Disease Market – Restraints

Lack of awareness regarding interstitial lung disease is projected to restrict the growth of the global interstitial lung disease market during the forecast period.

For instance, in August 2021, an educational webinar was held to drive awareness of interstitial lung disease (ILD), nine organizations collaborated to present the first-ever Interstitial Lung Disease Day (ILD) on, September 15. ILD is a term which refers to more than 200 types of lung diseases, which are characterized by inflammation and scarring in the lungs. The inflammation and scarring injures the lungs, making it difficult to breathe. Nine organizations include Pulmonary Fibrosis Foundation, Arthritis Foundation, Foundation for Sarcoidosis Research, The Myositis Association, PF Warriors LLC, Scleroderma Foundation, Scleroderma Research Foundation, Sjögren’s Foundation, Inc., and WESCOE Foundation.

Global Interstitial Lung Disease Market – Regional Analysis

On the basis of region, the global interstitial lung disease market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global interstitial lung disease market, owing to increasing number of drug approvals by regulatory bodies.

Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/4798

For instance, in March, 2021, F. Hoffmann-La Roche Ltd, a biotech company, announced that the U.S. Food and Drug Administration (FDA) approved Actemra/RoActemra (tocilizumab) subcutaneous injection for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), a debilitating condition with limited treatment options. Actemra/RoActemra is the first biologic therapy approved by the US FDA for the treatment of the disease.

Global Interstitial Lung Disease Market – Competitive Landscape

Key players operating in the global interstitial lung disease market include MSD (Merck), Liminal Biosciences, Glenmark Pharma, J.B. Chemicals & Pharmaceuticals, Boehringer Ingelhim International GmbH, F. Hoffmann-La Roche Ltd, Inc., and Cipla.

Buy This Report with Flat USD 2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/4798

Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Interstitial Lung Disease Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Interstitial Lung Disease Industry Impact

Chapter 2 Global Interstitial Lung Disease Competition by Types, Applications, and Top Regions and Countries
2.1 Global Interstitial Lung Disease (Volume and Value) by Type
2.3 Global Interstitial Lung Disease (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global Interstitial Lung Disease Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 North America Interstitial Lung Disease Market Analysis
Chapter 6 East Asia Interstitial Lung Disease Market Analysis
Chapter 7 Europe Interstitial Lung Disease Market Analysis
Chapter 8 South Asia Interstitial Lung Disease Market Analysis
Chapter 9 Southeast Asia Interstitial Lung Disease Market Analysis
Chapter 10 Middle East Interstitial Lung Disease Market Analysis
Chapter 11 Africa Interstitial Lung Disease Market Analysis
Chapter 12 Oceania Interstitial Lung Disease Market Analysis
Chapter 13 South America Interstitial Lung Disease Market Analysis
Chapter 14 Company Profiles and Key Figures in Interstitial Lung Disease Business
Chapter 15 Global Interstitial Lung Disease Market Forecast (2022-2028)
Chapter 16 Conclusions
Research Methodology